Comparative Outcomes of Ulcerative Colitis Patients With Mayo Endoscopic Score 1 and Histologic Activity Versus Mayo Endoscopic Score 2

IRCCS San Raffaele159 enrolled

Overview

This retrospective study examines patients with ulcerative colitis who initiated advanced therapy for their disease. In clinical practice, patients with only mild inflammation on endoscopy (Mayo Endoscopic Subscore 1, or MES1) often do not undergo treatment optimization or therapy change. We stratified these patients based on histologic findings from biopsy samples and compared them with patients who had greater endoscopic activity (MES2). We evaluated long-term outcomes, including surgery and hospitalization, to determine whether current management strategies for patients with mild endoscopic disease should be reconsidered.

Study Type

OBSERVATIONAL

Enrollment

159

Conditions

Ulcerative Colitis (UC)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed diagnosis of UC (by routine clinical, radiographic, endoscopic and pathologic criteria); * Patients starting a new advanced treatment for UC (either biologic agents or small molecules); * Patients with endoscopic MES of 1 or 2 at the endoscopic reassessment (conducted after 12 ± 3 months following the initiation of advanced therapy) Exclusion Criteria: * Patients with unclassified colitis or Crohn's disease; * Previous colonic surgery (eg. Pouch); * Patients for whom biopsies were not obtained at the time of endoscopic reassessment (conducted after 12 months following the initiation of advanced therapy);

Locations (1)

Outcomes

Primary Outcomes

Incidence of Composite Outcome

The composite outcome includes any of the following events: escalation of medical therapy, hospitalization related to ulcerative colitis, or surgery related to ulcerative colitis

Time frame: From enrollment to end of follow-up at 36 months